Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modakafusp Alfa Phase II in Relapsed/Refractory Multiple Myeloma
CTR20223441Phase 2Completed
- Sponsor
- Takeda
- Start
- Jan 2023
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of modakafusp alfa in multiple myeloma (MM), sponsored by Takeda. Started Jan 2023; status: completed.
02
Drugs
modakafusp alfa
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20223441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223441.